

Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?

Xavier Mignard, Anne-Marie Ruppert, Armelle Lavolé, Thibault Vieira, Nathalie Rozensztajn, Jacques Cadranel, Marie Wislez

▶ To cite this version:

Xavier Mignard, Anne-Marie Ruppert, Armelle Lavolé, Thibault Vieira, Nathalie Rozensztajn, et al.. Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?. Bulletin du Cancer, 2019, 106 (9), pp.725-733. 10.1016/j.bulcan.2019.04.010. hal-02404406

HAL Id: hal-02404406 https://hal.sorbonne-universite.fr/hal-02404406

Submitted on 11 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	
2	
3	
4	
F	
5	
6	
7	Is chemotherapy rechallenge feasible in advanced-stage
8	non-small-cell lung cancer?
9	La ré-introduction de chimiothérapie est-elle faisable au
10	cours du traitement du cancer pulmonaire non à petites
11	cellules de stade avancé?
12	
12	
13	
14	
15	Short title: Chemotherapy rechallenge in advanced NSCLC
16	Titre court: La ré-introduction de chimiothérapie dans le CBNPC de stade avancé
17	
18 19	Xavier Mignard ² , Anne-Marie Ruppert ¹ , Armelle Lavolé ¹ , Thibault Vieira ³ , Nathalie Rozensztajn ¹ , Jacques Cadranel ¹ , Marie Wislez ^{1,2}
20	¹ AP-HP, Tenon University Hospital, Pneumology department, F-75970, Paris, France
21	² Sorbonne Universités, UPMC Univ Paris 06, GRC n°04, Theranoscan, F-75252, Paris, France
22	³ Institut Mutualiste Montsouris, Pneumology department, Paris, France
23	
24	
25	Corresponding author: Marie Wislez (marie.wislez@aphp.fr)
26	

27 Abstract

28 Background:

29 Despite recent progress, non-small cell lung cancer (NSCLC) first-line treatment remains a 30 platinum-based doublet in most cases. No guidelines exist beyond third line. Chemotherapy 31 rechallenge is an option, but little data is available in NSCLC. Our study aims to describe patients 32 who underwent chemotherapy rechallenge while assessing its efficacy and safety.

33 Methods:

Consecutive patients with advanced-stage NSCLC receiving first-line treatment in Tenon hospital in 2011 were included, with a 5-year follow-up. Patients were analyzed according to chemotherapy rechallenge or not. Chemotherapy rechallenge was defined as re-initiation of a previously administered chemotherapy agent at any point in the treatment sequence, with at least one treatment regimen between first use and rechallenge.

39 **Results**:

Of 149 patients, 18 underwent chemotherapy rechallenge (12%). They were younger (56 vs. 61 40 years, p=0.04), mostly women (61% vs. 30%, p=0.02), with lepidic adenocarcinoma (23% vs. 3.5%, 41 p=0.03), a better general state of health (100% performance status 0–1 vs. 74%, p=0.04), and fewer 42 cardiovascular comorbidities (16% vs. 42%, p=0.04). They were more likely to have received a 43 44 receptor tyrosine kinase inhibitor treatment (89% vs. 43%, p=0.0003). Progression-free survival was longer at first use than at rechallenge (median 9.2 vs. 2.7 months, p=0.002). No increased toxicity 45 was observed at rechallenge compared to first use. Finally, a subsequent line of treatment was given 46 after rechallenge in 61% of the patients. 47

48 **Conclusion**:

49 Patients eligible for chemotherapy rechallenge were those with good prognostic factors.
50 Chemotherapy rechallenge may provide a well-tolerated additional line of treatment, with decreased
51 efficacy compared to its first application.

- 52
- 53

54 Keywords

- 55 NSCLC, chemotherapy, rechallenge
- 56

57 **Résumé**

58 Introduction:

59 Malgré des progrès récents, le traitement de première ligne des cancers broncho-pulmonaires non à

60 petites cellules (CBNPC) reste majoritairement un doublet à base de platine. Il n'existe pas de

61 recommandations après la troisième ligne. La ré-introduction de chimiothérapie est une option, mais

- 62 peu de données sont disponibles. Notre étude vise à décrire les patients ayant eu une ré-introduction
- 63 de chimiothérapie, ainsi que sa faisabilité et sa tolérance.

64 Méthodes:

Les patients consécutifs avec un CBNPC de stade avancé ayant reçu un traitement de première ligne à l'hôpital Tenon en 2011 ont été inclus. Ceux ayant eu une ré-introduction de chimiothérapie ont été comparés aux autres. Celle-ci était définie par la ré-utilisation d'un agent de chimiothérapie utilisé antérieurement, avec au moins une ligne entre la primo-utilisation et la ré-utilisation.

69 **Résultats**:

70 Parmi 149 patients, 18 ont eu une ré-introduction de chimiothérapie (12%). Il étaient plus jeunes

71 (56 ans vs. 61, p=0.04), de sexe féminin (61% vs. 30%, p=0.02), avec un adénocarcinome lépidique

72 (23% vs. 3.5%, p=0.03), un meilleur état général (PS 0-1: 100% vs. 74%, p=0.04) et moins de

comorbidités cardiovasculaires (16% *vs.* 42%, p=0.04). La survie sans progression était plus longue

74à la primo-utilisation qu'à la ré-introduction (médiane 9.2 mois vs. 2.7, p=0.002). Il n'y avait pas de

r5 surcroît de toxicité à la ré-introduction. Enfin, une ligne supplémentaire était possible après ré-

76 introduction chez 61% des patients.

77 **Conclusion**:

La ré-introduction de chimiothérapie fournit une ligne supplémentaire de traitement bien tolérée,
avec une efficacité moindre par rapport à la primo-utilisation.

- 80
- 81

82 Mots-clés

- 83 CBNPC, chimiothérapie, ré-introduction
- 84
- 85

86 Introduction

Despite recent progress, mortality from non-small-cell lung cancer (NSCLC) remains high. 87 During the last decade, therapeutic advances have included targeted therapies, mainly small-88 89 molecule tyrosine kinase receptor inhibitors (TKIs) [1]. However, these advances involve nonsquamous NSCLC only, and targetable anomalies are harbored by a minority of NSCLC patients, 90 for instance by 10 to 15% for EGFR [2], by around 5% for ALK [3], and by less than 2% for ROS1. 91 More recently, immunotherapy in the form of checkpoint inhibitors, such as anti-PD-1 92 (Programmed Death 1) and anti-PD-L1 (Programmed Death Ligand 1) antibodies, have resulted in 93 improved overall survival in second-line [4,5] for all comers and in first-line therapy, but only in 94 95 patients with strong PD-L1 expression (>50%) [6].

In patients who are ineligible for TKIs or immunotherapy, which remains the majority of 96 patients, standard first-line treatment consists of a platinum-based chemotherapy doublet combined 97 with pemetrexed, paclitaxel, gemcitabine, or vinorelbine [7]. This standard is also recommended for 98 progressive patients after first-line immunotherapy (more than 40% at six months of treatment). The 99 use of either cisplatin or carboplatin depends on age, performance status, and comorbidities like 100 chronic kidney or heart failure [8]. The benefit of a second-line treatment has been proven for 101 pemetrexed [9], docetaxel [10], erlotinib [11], and immunotherapy [4]. Third-line treatment proves 102 also effective for eligible patients [12,13], without any guidelines for treatment beyond this point. 103

Rechallenge with a conventional cytotoxic chemotherapy may be attempted if the disease 104 has initially responded. Chemotherapy rechallenge is recommended in other cancer treatments. 105 Pemetrexed rechallenge is indicated in malignant pleural mesothelioma when initial progression-106 free survival exceeds 12 months [14]. In disseminated relapsing small-cell lung cancer, rechallenge 107 with a platinum doublet plus etoposide is considered an option in platinum-sensitive disease [15]. In 108 the same manner, carboplatin rechallenge is common practice in platinum-sensitive relapsing 109 ovarian cancer [16]. In metastatic castration-resistant prostate cancer, taxanes like docetaxel or 110 cabazitaxel can likewise be reintroduced [17]. Following its introduction, immunotherapy became 111 an additional treatment option; prior to its advent, chemotherapy rechallenge was practiced 112 whenever other alternatives proved scarce. Chemotherapy rechallenge may still be worth 113 considering, especially after progression on immunotherapy. Rechallenge with the various 114 115 immunotherapy agents is presently being discussed. Little data currently exists on chemotherapy rechallenge in NSCLC. This work sought to better describe the characteristics of patients who 116

- underwent chemotherapy rechallenge in a retrospective study, while assessing the efficacy and
- 118 safety of this practice.

120 **Patients and Methods**

121 Inclusion criteria

All consecutive adult patients with advanced-stage NSCLC receiving first-line treatment from 122 January 1, 2011, to December 30, 2011, in a French university hospital were included. Advanced-123 stage NSCLC was defined as Stage IIIB (ineligible for curative therapy) and Stage IV NSCLC 124 according to the 7th edition of the International Association for the Study of Lung Cancer (IASLC) 125 classification. First-line treatment consisted of either chemotherapy or TKI for patients with 126 oncogenic addiction. Patients with metastatic relapse after previous curative surgery could be 127 included. Neo-adjuvant or adjuvant chemotherapy as well as radiotherapy were accepted and were 128 not considered as a first-line treatment. Patients list was generated from the chemotherapy 129 prescription software. 130

131

132 Data collection

The following data were collected: age at diagnosis; gender; smoking history, namely number of 133 pack-years, years of smoking, and current smoking status defined as never-smoker (<100 cigarettes 134 in life), former smoker (>100 cigarettes in life but stopped >1 year) or current smoker (>100 135 cigarettes in life and either still smoking or stopped <1 year); performance status at diagnosis 136 according to the ECOG scale; disease stage according to the 7th edition of the IASLC clinical TNM 137 classification; occurrence of central nervous system (CNS) or sub-diaphragmatic metastases. 138 Comorbidities like cardiovascular diseases (high blood pressure, stroke, myocardial ischemia, or 139 arteriosclerosis obliterans), diabetes, neoplasms of other organs, chronic respiratory failure (CRF) 140 or chronic obstructive pulmonary disease (COPD), chronic renal failure, HIV infection, psychiatric 141 disorder, or alcoholism were recorded. Histological types were defined according to the 2004 WHO 142 classification [18] as adenocarcinoma, squamous-cell carcinoma, large cell carcinoma, and 143 sarcomatoid carcinoma. Adenocarcinoma subtypes were defined as acinar, mucinous, lepidic, 144 papillary or undifferentiated. Oncogenic addiction was defined as EGFR mutation or ALK or ROS1 145 rearrangement. ALK or ROS1 rearrangements were detected by immunohistochemistry and 146 confirmed by fluorescence in situ hybridization. EGFR, KRAS, BRAF, HER2, and PI3KCA 147 mutations were screened by previously described techniques [19]. The number of treatment lines 148 received by each patient, including targeted therapies, and for each line of treatment were recorded, 149

as well as its duration, how many cycles were administered (including maintenance if relevant), andwhether the dose was reduced. Patients were treated in accordance with routine clinical care.

152 Chemotherapy rechallenge was defined as the re-use of a drug that had been administered earlier in 153 the course of treatment and stopped due to disease progression or toxicity. At least one line of 154 treatment had to have been received between first use and re-use. Resuming treatment after a break 155 was not considered rechallenge, even if treatment was halted for a long period. The same agent had 156 to be used, except for platinum-derived products like cisplatin or carboplatin. Re-using an agent as 157 monotherapy when it was first used in a platinum-based doublet was considered as a rechallenge 158 (Fig. 1). Rechallenge with targeted therapy was not taken into account for this study.

159

160 The following data were collected for each chemotherapy rechallenge: treatment duration, 161 performance status at rechallenge, number of previous lines, use as maintenance or not, 162 progression-free survival at first-use and at rechallenge, line of treatment after rechallenge, and 163 toxicity (hematological, gastrointestinal, or other) graded according to the WHO classification. 164 Rechallenged patients were divided into five groups: platinum-based doublet or triplet 165 (cisplatin/carboplatin + other agent \pm bevacizumab), or pemetrexed, gemcitabine, paclitaxel and 166 vinorelbine monotherapy.

167

168 Statistical analyses

Patients were analyzed according to whether they received chemotherapy rechallenge or not. 169 Continuous variables were expressed as median and associated range [min-max]. Categorical 170 variables were expressed as percentages. Comparisons between non-parametric continuous 171 variables were conducted using the Mann-Whitney test. Comparisons between categorical variables 172 were conducted by means of the the Chi-squared test or Fisher's exact test when the number of 173 observations was less than 5. Progression-free survival rates at first use and at rechallenge were 174 175 compared with the Wilcoxon test. Toxicity at first use and at rechallenge were compared using McNemar's Chi-squared test. Results were considered statistically significant when p <0.05. 176 Analyses were performed with SPSS 20.0 (IBM France) software. Data were reviewed by a 177 statistician. 178

180 Ethics and regulations

181 The local database was declared, and it obtained authorization from the bodies that monitor the182 application of data privacy laws according to French guidelines.

184 **Results**

185 Patients characteristics

186 In 2011, 149 patients underwent first-line treatment for advanced-stage NSCLC, in our French university hospital. Median age was 60 years [36–87]. Overall, 66% of the patients were men, 187 47.5% were smokers, 39% were former smokers, and 8.5% were never-smokers. Histology showed 188 66.5% had adenocarcinoma, 21% squamous-cell carcinoma, 10.5% large cell carcinoma, and 2% 189 sarcomatoid carcinoma. Among non-squamous NSCLCs, 6.5% were EGFR mutated, 16% KRAS 190 mutated, 0.5% BRAF mutated, and 5% harbored ALK rearrangement. No ROS1 rearrangement was 191 192 observed. The mutation status of 11 patients (7.5%) was unknown. Regarding comorbidities, 39% of the patients had at least one cardiovascular comorbidity, 11.5% had diabetes, 14.5% had a 193 194 current neoplasm or had had a prior neoplasm in another organ, and 11.5% had either CRF or COPD. Most patients were in good general condition (77% had a performance status of 0-1) at 195 first-line treatment. Patients received a mean of 2.8, or a median of 2.0 [1–11], treatment lines, and 196 almost half of them received TKI (regardless of mutation status) in accordance with current 197 guidelines. 198

199

200 Characteristics of chemotherapy rechallenge

Altogether, 18 of 149 patients (12%) underwent chemotherapy rechallenge: 13 had asingle rechallenge and five two rechallenges with different agents. Hence, 23 distinct rechallenges were noted across our five groups, namely eight rechallenges with a platinum-based doublet (carboplatin, n=5; cisplatin, n=3), seven with pemetrexed, four with gemcitabine, three with paclitaxel and one with vinorelbine. No rechallenge with docetaxel was observed.

The median number of cycles was 4 [1-16] at both first use and rechallenge. For platinum-based doublets, the median cycle number at rechallenge was 4 [2-5] *versus* 4 [4-5] at first use. The median cycle number was lower at rechallenge than at first use for pemetrexed (3 [2-8] *vs.* 7 [1-16]) and for gemcitabine (2 [1-16] *vs.* 5.5 [4-8]). At rechallenge, patients were mostly at their fourth line of treatment (4 [3-6]) and mostly (78%) with a favorable PS (0-1). A subsequent line of treatment was feasible in 61% of patients. Pemetrexed and gemcitabine were initially used as maintenance therapy in respectively 43 and 50% of the patients (Table 1).

Characteristics of patients according to chemotherapy rechallenge

In univariate analyses, rechallenged patients were younger (median age 56 vs. 61 years, p = 0.04), 215 were more often women (61% vs. 30.5%, p = 0.021), had fewer cardiovascular comorbidities 216 (16.5% vs. 42%, p = 0.039), and had a better PS (100% 0–1 performance status at diagnosis vs. 217 74%, p = 0.043). Rechallenged patients tended to smoke less (median smoking duration of 30.5 vs. 218 40 years, p = 0.086). They received a higher number of treatment lines (median 5.0 vs. 2.0, p 219 <0.0001) and received a targeted therapy (TKI) more often (89% vs. 43.5%, p = 0.0003), regardless 220 221 of the presence or absence of oncogenic addiction. A higher proportion of adenocarcinomas was noted in rechallenged patients (72% vs. 65% other histology, p = 0.57) particularly of the lepidic 222 subtype (23% vs. 3.5%, p = 0.037). No difference was found according to EGFR or ALK status. 223 KRAS-mutated patients tended to be less rechallenged than others (1/24 rechallenged vs. 23/24 not 224 rechallenged, p = 0.18) (tables 2 and 3). Regarding overall survival, patients with chemotherapy 225 226 rechallenge had a longer overall survival (median 32.7 months vs. 13.4 months, p = 0.0002).

227

228 **Progression-free survival at first use and rechallenge**

Progression-free survival was shorter at rechallenge than at first use, namely 2.7 months [0.2-22.5]*versus* 9.2 months [2.7-31.6] (p = 0.0021). Progression-free survival by drug is given in Table 4.

231

232 Toxicity at first use and rechallenge

During the 23 rechallenges, at least one Grade-3 or -4 toxicity was observed in seven cases (30%) at first use and in five cases (24%) at rechallenge (p = 0.62). No toxicity gain was found at rechallenge compared to first use, except one case of Grade-4 neutropenia during paclitaxel rechallenge. Toxicity was mostly hematological. There was no Grade-3 or -4 neurological or renal toxicity (data not shown) nor iatrogenic death.

239 **Discussion**

Of 149 patients with advanced NSCLC, 18 underwent at least one chemotherapy rechallenge during treatment, with five being rechallenged twice. Hence, we recorded a total of 23 distinct rechallenges. The most commonly used drugs for rechallenge were pemetrexed and platinum-based doublets, which were given in, respectively, 7 and 8 cases. Rechallenge was carried out with gemcitabine in four cases, with paclitaxel in three cases, and with vinorelbine in one case.

Those who received chemotherapy rechallenge were characterized as patients exhibiting favorable prognostic factors. Younger age, female gender, better general condition, fewer comorbidities, and lepidic histological subtype have previously been shown to be associated with longer overall survival [20],[21],[22]. Our results are consistent with the study of Girard *et al.*, in which patients who benefited the most from third-line therapy were those with good prognostic factors [13].

KRAS-mutated patients received chemotherapy rechallenge less than others (1 patient rechallenged *vs.* 23 non-rechallenged, p = 0.18). *KRAS* mutation seems to be associated with worse survival for patients with advanced NSCLC [23], but its involvement in chemotherapy resistance is still debatable [24].

Progression-free survival at rechallenge was 2.7 months for all treatments, which was significantly shorter than progression-free survival at first use (9.2 months). For platinum-based doublets, progression-free survival at rechallenge was non-significantly shorter (3.0 months) than at first use (7.4 months), which might be due to lack of statistical power. For pemetrexed, progressionfree survival was significantly shorter at rechallenge (2.5 months) than at first use (7.7 months). The longest progression-free survival at rechallenge was obtained with paclitaxel (5.4 months) and the shortest with gemcitabine (1.8 months).

Petrelli et al. reported a progression-free survival of 3.9 months with platinum/pemetrexed 262 rechallenge in a pooled analysis of 11 studies [25]. In a retrospective study, when pemetrexed 263 rechallenge was given as monotherapy or as combination therapy with a platinum salt, it showed a 264 progression-free survival of 3.8 months in a second-line setting only [26]. Median age was similar 265 and patients were in good general condition (97% had a performance status of 1). In both studies, 266 patients were rechallenged earlier than in ours (second line vs. fourth), which may explain why they 267 observed longer progression-free survival. In another retrospective study, 25 patients had 268 pemetrexed rechallenge [27]. Progression-free survival was shorter (1.5 month). The patients were 269

mostly men (64%) and mostly had a performance status of 2 (60%). The discrepancies between all
these studies may be due to their retrospective design and small sample sizes.

In our study, Grade-3 or -4 toxicities did not increase at rechallenge except for one patient with paclitaxel (Grade-4 neutropenia). A rise in toxicity could have been expected, since chemotherapy rechallenge is practiced on heavily pre-treated patients. For example, docetaxel rechallenge in metastatic castration-resistant prostate cancer is risky, owing to cumulative neurotoxicity [17]. No cumulative toxicity was found in our study, especially no renal toxicity.

277 A further line of treatment was administered after rechallenge in 61% of our patients. The rechallenge was not, therefore, their last line of treatment, which suggests that their general 278 279 condition permitted them to receive the additional treatment line. PFS was shorter at rechallenge than at first-use in our study. These results are coherent with other studies describing a decreased 280 281 disease control between first-line and subsequent lines [28]. This retrospective study does not answer the question of whether rechallenge proves cost-effective or of benefit in terms of quality of 282 life. Our study reflects the realities of routine practice in this patient population. Immune checkpoint 283 inhibitors are considered a new option and may delay the need for chemotherapy rechallenge in the 284 course of the disease. Our study's limitations were its retrospective design, single-center data, small 285 sample size, and heterogeneity of administered treatments (including those administered twice). 286 However, our findings may further improve our understanding of chemotherapy rechallenge. 287

288

289 **Conclusion**

Of 149 patients with advanced NSCLC, 18 (12%) underwent chemotherapy rechallenge. These patients had good prognostic factors. Progression-free survival was shorter at rechallenge than at first use. No toxicity gain was noted at rechallenge. Thus chemotherapy rechallenge should be considered a treatment option in suitable patients.

295 Acknowledgments

The authors wish to thank Dr. Pierre Levy for his review of the statistics, Mr. J. Rose for his help generating the list of patients, Ms. V. Poulot and Ms. L. Pinon for their help with molecular and histological data, and Ms. N. Mathiot and Ms. G. Pontdeme for their overall contribution to this work.

Figure 1: Illustration of chemotherapy rechallenge in the course of treatment

Figure 1: The x-axis represents treatment course. Re-use of a platinum salt was considered as platinum salt rechallenge, regardless of the drug it was combined with. Re-use of an agent as monotherapy when it was first used in a platinum-based doublet was considered as a rechallenge.

305

	Characteristics of rechallenge according to drug						
Variable –	All <i>n=23</i>	Platinum + X n=8	Pemetrexed n=7	Gemcitabine n=4	Paclitaxel n=3	Vinorelbine n=1	
Number of cycles at first use							
Median	4	4	7	5.5	4	5	
[range]	[1–16]	[4–5]	[1–16]	[4-8]	[4-4]	[5–5]	
Initially used as maintenance	NA*	NA	3 (43)	2 (50)	NA	NA	
Performance status at rechallenge							
0 - 1	18 (78)	7 (87.5)	5 (71)	3 (75)	100 (0)	0 (0)	
2	5 (22)	1 (12.5)	2 (29)	1 (25)	0 (0)	1 (100)	
Histology							
Adenocarcinoma	17 (74)	6 (75)	6 (86)	2 (50)	3 (100)	0 (0)	
Squamous cell carcinoma	4 (17)	2 (25)	0 (0)	1 (25)	0 (0)	1 (100)	
Large cell carcinoma	1 (4.5)	0 (0)	0 (0)	1 (25)	0 (0)	0 (0)	
Sarcomatoid carcinoma	1 (4.5)	0 (0)	1 (14)	0 (0)	0 (0)	0 (0)	
Number of lines at rechallenge							
Median	4	4	5	4.5	3	5	
[range]	[2-6]	[2-6]	[2–6]	[3–5]	[2-4]	[5-5]	
Number of cycles at rechallenge							
Median	4	4	3	2	6	2	
[range]	[1–16]	[2–5]	[2-8]	[1–16]	[5-7]	[2–2]	
Subsequent line of treatment after rechallenge 309	14 (61)	6 (75)	4 (57)	2 (50)	2 (67)	0 (0)	

310 *NA= not applicable

Variable	Overall <i>n=99</i>	Rechallenged n=13	Not rechallenged n=86	Univariate analysis	
	n (%)	n (%)	n (%)	(p)	
Adenocarcinoma					
histologic subtype					
Acinar	26 (26.5)	3 (23)	23 (26.5)	p = 0.74	
Mucinous	14 (14)	3 (23)	11 (13)	p = 0.42	
Lepidic	6 (6)	3 (23)	3 (3.5)	p = 0.037	
Papillary	3 (3)	0 (0)	3 (3.5)	p = 1.0	
Undifferentiated	34 (34.5)	3 (23)	31 (36)	NC*	
Unknown	16 (16)	1 (8)	15 (17.5)	NC	

*NC = not calculated

 $\label{eq:21} 317 \qquad \text{Comparisons between categorical variables were conducted with the Chi-squared test or Fisher's exact test when n < 5.$

Table 3: Characteristics of rechallenged and non-rechallenged patients

Variable	Rechallenged <i>n</i> = <i>18</i> n (%) or median [range]	Not rechallenged <i>n</i> = <i>131</i> n (%) or median [range]	Univariate analysis (p)	
Age (years)	56 [42–72]	61 [36–87]	p = 0.04	
Gender				
Male	7 (39)	91 (69.5)	p = 0.021	
Female	11 (61)	40 (30.5)	•	
Smoking history				
Non-smoker	2 (11)	11 (8.5)	p = 0.87	
Former smoker	8 (44.5)	50 (38)	p = 0.07	
Current smoker	8 (44.5) 8 (44.5)	63 (48)		
			n = 0.21	
Pack-years	39 [0–92]	40 [0-150]	p = 0.21	
Smoking duration (years)	30.5 [0–53]	40 [0-64]	p = 0.086	
Histology				
Adenocarcinoma	13 (72.5)	86 (65)	p = 0.57	
Squamous cell carcinoma	3 (16.5)	28 (21.5)	p = 0.77	
Large cell carcinoma	1 (5.5)	15 (12)	p = 0.69	
Sarcomatoid carcinoma	1 (5.5)	2 (1.5)	NC	
	- (- ()		
Mutations (*)		0.40	0.44	
EGFR mutation	2 (11)	8 (6)	p = 0.61	
ALK rearrangement	1 (5.5)	6 (4.5)	p = 1.0	
KRAS mutation	1 (5.5)	23 (17.5)	p = 0.18	
BRAF mutation	0 (0)	1 (1)	NC	
No mutation	10 (55.5)	55 (42)	NC	
Initial stage				
IA–IIIA	2 (11)	18 (14)	p = 1.0	
IIIB/IV	16 (89)	112 (86)	P	
Metastases at diagnosis		. ,		
CNS	3 (16.5)	32 (24.5)	p = 0.56	
Subdiaphragmatic	6 (33.5)	47 (36)	p = 0.30 p = 0.84	
	0 (33.3)	47 (30)	p = 0.84	
Comorbidities	0 (50) (0 (50)	05 (65) (46 (05)	0.00	
Yes/No	9 (50)/9 (50)	85 (65)/46 (35)	p = 0.22	
Cardiovascular comorbidities	3 (16.5)	55 (42)	p = 0.039	
Diabetes	1 (5.5)	16 (12)	p = 0.7	
Other neoplasm	2 (11)	20 (15.5)	p = 1.0	
CRF/COPD	2 (11)	15 (11.5)	p = 1.0	
Chronic renal failure	0 (0)	3 (2.5)	p = 1.0	
HIV	1 (5.5)	1 (1)	p = 0.23	
Psychiatric comorbidity	4 (22)	8 (6)	p = 0.04	
Alcoholism	0 (0)	5 (4)	p = 1.0	
Performance status at diagnosis				
0–1	18 (100)	97 (74)	p = 0.043	
2-4	0 (0)	23 (17.5)	E	
Number of treatment lines				
Mean	5.5	2.4	p < 0.0001	
1–3 lines	2 (11)	99 (76)	.	
> 3 lines	16 (89)	32 (24)		
Targeted therapy (TKI) received	16 (89)	57 (43.5)	p = 0.0003	
No oncogenic addiction	13 (72)	44 (34)	p = 0.0005 p = 0.044	

322 Comparisons between non-parametric continuous variables were conducted with the Mann-Whitney test. Comparisons between categorical variables

 $\label{eq:second} \mbox{were conducted with the Chi-squared test or Fisher' exact test when $n < 5$. (*) Mutational status research doesn't include patients with squamous$

324 histology (n=31). Among patients with non-squamous histology, 11 have unknown mutational status.a

325 Table 4: Progression-free survival according to first use and rechallenge for each drug

_

	Rechallenge according to drug					
Variable	All <i>n=23</i>	Platinum+X <i>n=8</i>	Pemetrexed n=7	Gemcitabine n=4	Paclitaxel n=3	Vinorelbine n=1
PFS at first use (months) Median [min-max]	9.2 [2.7–31.7]	7.4 [4.3–15.7]	7.7 [2.7–12.8]	9.2 [8.7–11.5]	7.1 [4.3–31.7]	15.7 [NA]
PFS at rechallenge (months) Median [min–max]	2.7 [0.25–22.5]	3.0 [1.0–22.5]	2.5 [1.0–6.6]	1.8 [0.25–12.1]	5.4 [4.5–6.3]	4.5 [NA]
Wilcoxon test	p = 0.002	p = 0.16	p = 0.027	NA*	NA	NA

328 *NA = not applicable; PFS = progression-free survival

Progression-free survival at first use and at rechallenge were compared with the Wilcoxon test.

333 **References**

Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-Year
 Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac
 Oncol Off Publ Int Assoc Study Lung Cancer. 2016 Apr;11(4):556–65.

Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling
pathway in lung cancers. Int J Cancer. 2006 Jan 15;118(2):257–62.

339 3. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing
multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol Off
J Eur Soc Med Oncol. 2011 Dec;22(12):2616–24.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus
 Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct
 22;373(17):1627–39.

5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J
Med. 2015 Jul 9;373(2):123–35.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al.
 Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J
 Med. 2016 10;375(19):1823–33.

351 7. Bluthgen M-V, Besse B. Second-line combination therapies in nonsmall cell lung cancer
352 without known driver mutations. Eur Respir Rev Off J Eur Respir Soc. 2015 Dec;24(138):582–93.

Smit E, Moro-Sibilot D, Carpeño J de C, Lesniewski-Kmak K, Aerts J, Villatoro R, et al.
 Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung
 cancer: Analysis from the European FRAME study. Lung Cancer Amst Neth. 2016 Feb;92:35–40.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung
cancer previously treated with chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004 May
1;22(9):1589–97.

Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective
randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2000
May;18(10):2095–103.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123–
32.

367 12. Song Z, Yu Y, Chen Z, Lu S. Third-line therapy for advanced non-small-cell lung cancer

- patients: feasible drugs for feasible patients. Med Oncol Northwood Lond Engl. 2011 Dec;28 Suppl
 1:S605-612.
- Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A, et al. Third-line
 chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine
 practice. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Dec;4(12):1544–9.
- 14. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al.
 Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
 Lung Cancer Amst Neth. 2011 Apr;72(1):73–7.
- 376 15. Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, et al.
 377 Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide
 378 Rechallenge: A Multi-Institutional Retrospective Analysis. Clin Lung Cancer. 2015
 379 Nov;16(6):e223-228.
- 380 16. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol.
 381 2003 Sep;90(3 Pt 2):S39-44.
- 382 17. Oudard S, Kramer G, Caffo O, Creppy L, Loriot Y, Hansen S, et al. Docetaxel rechallenge
 after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU
 384 Int. 2015 May;115(5):744–52.
- 18. Travis WD, Cancer IA for R on. Pathology and genetics of tumours of the lung, pleura,
 thymus and heart. IARC; 2004. 349 p.
- Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, et al. Crossvalidation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded
 non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French
 laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in nonsmall cell lung carcinoma [ERMETIC] project--part 1). J Thorac Oncol Off Publ Int Assoc Study
 Lung Cancer. 2011 Jun;6(6):1006–15.
- Sculier J-P, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, International Staging
 Committee and Participating Institutions. The impact of additional prognostic factors on survival
 and their relationship with the anatomical extent of disease expressed by the 6th Edition of the
 TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol Off
 Publ Int Assoc Study Lung Cancer. 2008 May;3(5):457–66.
- 398 21. Grose D, Morrison DS, Devereux G, Jones R, Sharma D, Selby C, et al. The impact of
 399 comorbidity upon determinants of outcome in patients with lung cancer. Lung Cancer Amst Neth.
 2015 Feb;87(2):186–92.
- 401 22. Hung J-J, Yeh Y-C, Jeng W-J, Wu K-J, Huang B-S, Wu Y-C, et al. Predictive value of the
 402 international association for the study of lung cancer/American Thoracic Society/European
 403 Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.
 404 J Clin Oncol Off J Am Soc Clin Oncol. 2014 Aug 1;32(22):2357–64.

- Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of
 RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with
 meta-analysis. Br J Cancer. 2005 Jan 17;92(1):131–9.
- 408 24. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J
 409 Clin Oncol Off J Am Soc Clin Oncol. 2013 Mar 10;31(8):1112–21.
- Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barni S. Platinum rechallenge in
 patients with advanced NSCLC: a pooled analysis. Lung Cancer Amst Neth. 2013 Sep;81(3):337–
 42.
- 26. Zhuo M-L, Bai H, Wang Z-J, Duan J-C, An T-T, Wu M-N, et al. Rechallenge with
 pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous
 non-small-cell lung cancer. Mol Clin Oncol. 2014 Nov;2(6):953–9.
- 416 27. Song Z, Zhang Y. Retreatment with pemetrexed chemotherapy in advanced non-small cell
 417 lung cancer patient. J Thorac Dis. 2014 Jun;6(6):856–60.
- 418 28. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, et al. A retrospective analysis of
- the outcome of patients who have received two prior chemotherapy regimens including platinum
- 420 and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer Amst Neth. 2003
- 421 Jan;39(1):55–61.




Figure 1: Representation of chemotherapy rechallenge in the course of treatment

The x-axis represents treatment course. Re-use of a platinum salt was considered as platinum salt rechallenge, regardless of the drug it was combined with. Re-use of an agent as monotherapy when it was first used in a platinum-based doublet was considered as a rechallenge.